ArticleNPJ breast cancer2025
Spatial proximity of CD8
Abstract read
In one paragraph
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.Gut microbes · 2026Review
- Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer.Hepatology (Baltimore, Md.) · 2026Review
- Scalable 3D cell-interaction analysis via supercell graphs for prostate cancer risk stratification.bioRxiv : the preprint server for biology · 2026Article
- Article
- Longitudinal spatial neutrophil profiling during ACT in murine melanoma reveals distinct lymph node infiltration patterns.NPJ systems biology and applications · 2026Article
- Review
- QuTILs: Open-Source Image-Based Infiltrating Immune Cell Detection for Research Application.Research square · 2026Article
- Multi‑scale immune and spatial profiling of sclerosing adenosis and surrounding breast tissue identifies an immune‑cold field phenotype associated with breast cancer risk.Breast cancer research : BCR · 2026Article
- Single-cell TCR mapping reveals spatially coordinated T cell states in head and neck cancer.Science immunology · 2026Article
- Mitochondria in T‑cell tumor immunity and tumor therapies targeting mitochondria (Review).Oncology reports · 2026Review
- Single-cell landscape of intratumoral heterogeneity and GABA-mediated remodeling of the immune microenvironment in breast cancer metastases.Breast cancer research : BCR · 2026Article
- DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.Clinical epigenetics · 2026Article
- TILseg: Automated Whole Slide-Level Spatial Scoring of Tumor-Infiltrating Lymphocytes Reveals Prognostic Patterns in Triple Negative Breast Cancer.medRxiv : the preprint server for health sciences · 2026Article
- The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.Breast cancer research : BCR · 2026Article
- Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation.Frontiers in immunology · 2026Review
- A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer.Therapeutic advances in medical oncology · 2026Article
- The Correlation Between CD8+ Tumor-Infiltrating Lymphocytes and the Efficacy of Neoadjuvant Therapy in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Spatial AI in cancer: mapping immune evasion topology through multi-modal omics and deep learning.Frontiers in oncology · 2026Review
- Spatial architecture of tumor-infiltrating lymphocytes adds predictive value beyond stromal TIL density for neoadjuvant response in triple-negative breast cancer.Frontiers in immunology · 2026Article
- Lumi-Guide: An Artificial-Intelligence-Driven Multimodal Framework for Optimizing Personalized Neoadjuvant Therapy Decision-Making in Luminal Breast Cancer.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Hongling LiangDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID http://orcid.org/0000-0001-5474-7888
Jianqing HuangDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Hongsheng LiDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Weixing HeDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Xiang AoDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Zhi XieMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Yu ChenMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Zhiyi LvMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Leyao ZhangDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID http://orcid.org/0009-0001-3720-3130
Yanhua ZhongDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID http://orcid.org/0009-0004-6934-1329
Xiaojun TanDepartment of Pathology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Guodong HanDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Jie ZhouDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Ni QiuDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Ming JiangDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Haoming XiaDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Yongtao ZhanDepartment of Breast Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Lei JiaoPanovue Biological Technology Co., Ltd, Beijing, 100000, China.
Jie MaPanovue Biological Technology Co., Ltd, Beijing, 100000, China.
Derek RadiskyDepartment of Cancer Biology Mayo Clinic Cancer Center, Jacksonville, FL, 32224, USA. Radisky.derek@mayo.edu.
Jia HuangSchool of Health Management, Guangzhou Medical University, Guangzhou, 511436, China. 850374937@qq.com.
Xuchao ZhangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China. zhxuchao3000@126.com.ORCID http://orcid.org/0000-0002-4138-8115
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spatial proximity of CD8
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.